Coming to terms with Vietnam: The Viet/American Cervical Cancer Prevention Project

Eric J. Suba, Amber D Donnelly, Lisa M. Furia, My Linh D Huynh, Stephen S. Raab

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The Viet/American Cervical Cancer Prevention Project embraces a dual mission. We seek to develop sustainable, cost-effective cervical cancer prevention services for women in Vietnam. Because the problem of cervical cancer in Vietnam is in part a legacy of the Second Indochinese War, we also seek to examine obstacles to reconciliation by presenting what most acknowledge to be a remedy in advance of what some will perceive to be an accusation. Certain research and commercial interests have produced obstacles to our dual mission in Vietnam. The Alliance for Cervical Cancer Prevention, supported by the Bill and Melinda Gates Foundation, has failed to endorse Pap screening for developing countries and is conducting clinical trials which may further disaffect medically underserved groups. Visual screening techniques combined with immediate ablative treatment methods are incompatible with the requirements of "first do no harm." Because the Pap smear will probably be a component of any future human papillomavirus (HPV)-based or visual-based screening programs, it serves the interests of those promoting noncytologic screening methods to also support the development of Pap screening services. Research on HPV screening in developing countries raises concerns of commercial exploitation. Because Pap screening is feasible wherever cervical screening is appropriate, it is inappropriate to delay the development of Pap screening services pending research into HPV vaccines or alternative screening technologies. Quality management is the point at which public health and diagnostic pathology intersect and will remain an indispensable element of cervical screening programs irrespective of the screening test(s) eventually used. Pap screening in developing countries is an ethical imperative without a substantial political constituency and will benefit from the engagement of organized cytology.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalDiagnostic cytopathology
Volume33
Issue number5
DOIs
StatePublished - Nov 1 2005

Fingerprint

Vietnam
Uterine Cervical Neoplasms
Developing Countries
Research
Papanicolaou Test
Papillomavirus Vaccines
Cell Biology
Public Health
Clinical Trials
Pathology
Technology
Costs and Cost Analysis
Therapeutics

Keywords

  • Cervical cancer
  • Developing countries
  • Ethics
  • Vietnam
  • War

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Coming to terms with Vietnam : The Viet/American Cervical Cancer Prevention Project. / Suba, Eric J.; Donnelly, Amber D; Furia, Lisa M.; Huynh, My Linh D; Raab, Stephen S.

In: Diagnostic cytopathology, Vol. 33, No. 5, 01.11.2005, p. 344-351.

Research output: Contribution to journalArticle

Suba, Eric J. ; Donnelly, Amber D ; Furia, Lisa M. ; Huynh, My Linh D ; Raab, Stephen S. / Coming to terms with Vietnam : The Viet/American Cervical Cancer Prevention Project. In: Diagnostic cytopathology. 2005 ; Vol. 33, No. 5. pp. 344-351.
@article{8feacea0eff14e2e8a6434f095b160e3,
title = "Coming to terms with Vietnam: The Viet/American Cervical Cancer Prevention Project",
abstract = "The Viet/American Cervical Cancer Prevention Project embraces a dual mission. We seek to develop sustainable, cost-effective cervical cancer prevention services for women in Vietnam. Because the problem of cervical cancer in Vietnam is in part a legacy of the Second Indochinese War, we also seek to examine obstacles to reconciliation by presenting what most acknowledge to be a remedy in advance of what some will perceive to be an accusation. Certain research and commercial interests have produced obstacles to our dual mission in Vietnam. The Alliance for Cervical Cancer Prevention, supported by the Bill and Melinda Gates Foundation, has failed to endorse Pap screening for developing countries and is conducting clinical trials which may further disaffect medically underserved groups. Visual screening techniques combined with immediate ablative treatment methods are incompatible with the requirements of {"}first do no harm.{"} Because the Pap smear will probably be a component of any future human papillomavirus (HPV)-based or visual-based screening programs, it serves the interests of those promoting noncytologic screening methods to also support the development of Pap screening services. Research on HPV screening in developing countries raises concerns of commercial exploitation. Because Pap screening is feasible wherever cervical screening is appropriate, it is inappropriate to delay the development of Pap screening services pending research into HPV vaccines or alternative screening technologies. Quality management is the point at which public health and diagnostic pathology intersect and will remain an indispensable element of cervical screening programs irrespective of the screening test(s) eventually used. Pap screening in developing countries is an ethical imperative without a substantial political constituency and will benefit from the engagement of organized cytology.",
keywords = "Cervical cancer, Developing countries, Ethics, Vietnam, War",
author = "Suba, {Eric J.} and Donnelly, {Amber D} and Furia, {Lisa M.} and Huynh, {My Linh D} and Raab, {Stephen S.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1002/dc.20284",
language = "English (US)",
volume = "33",
pages = "344--351",
journal = "Diagnostic Cytopathology",
issn = "8755-1039",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Coming to terms with Vietnam

T2 - The Viet/American Cervical Cancer Prevention Project

AU - Suba, Eric J.

AU - Donnelly, Amber D

AU - Furia, Lisa M.

AU - Huynh, My Linh D

AU - Raab, Stephen S.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - The Viet/American Cervical Cancer Prevention Project embraces a dual mission. We seek to develop sustainable, cost-effective cervical cancer prevention services for women in Vietnam. Because the problem of cervical cancer in Vietnam is in part a legacy of the Second Indochinese War, we also seek to examine obstacles to reconciliation by presenting what most acknowledge to be a remedy in advance of what some will perceive to be an accusation. Certain research and commercial interests have produced obstacles to our dual mission in Vietnam. The Alliance for Cervical Cancer Prevention, supported by the Bill and Melinda Gates Foundation, has failed to endorse Pap screening for developing countries and is conducting clinical trials which may further disaffect medically underserved groups. Visual screening techniques combined with immediate ablative treatment methods are incompatible with the requirements of "first do no harm." Because the Pap smear will probably be a component of any future human papillomavirus (HPV)-based or visual-based screening programs, it serves the interests of those promoting noncytologic screening methods to also support the development of Pap screening services. Research on HPV screening in developing countries raises concerns of commercial exploitation. Because Pap screening is feasible wherever cervical screening is appropriate, it is inappropriate to delay the development of Pap screening services pending research into HPV vaccines or alternative screening technologies. Quality management is the point at which public health and diagnostic pathology intersect and will remain an indispensable element of cervical screening programs irrespective of the screening test(s) eventually used. Pap screening in developing countries is an ethical imperative without a substantial political constituency and will benefit from the engagement of organized cytology.

AB - The Viet/American Cervical Cancer Prevention Project embraces a dual mission. We seek to develop sustainable, cost-effective cervical cancer prevention services for women in Vietnam. Because the problem of cervical cancer in Vietnam is in part a legacy of the Second Indochinese War, we also seek to examine obstacles to reconciliation by presenting what most acknowledge to be a remedy in advance of what some will perceive to be an accusation. Certain research and commercial interests have produced obstacles to our dual mission in Vietnam. The Alliance for Cervical Cancer Prevention, supported by the Bill and Melinda Gates Foundation, has failed to endorse Pap screening for developing countries and is conducting clinical trials which may further disaffect medically underserved groups. Visual screening techniques combined with immediate ablative treatment methods are incompatible with the requirements of "first do no harm." Because the Pap smear will probably be a component of any future human papillomavirus (HPV)-based or visual-based screening programs, it serves the interests of those promoting noncytologic screening methods to also support the development of Pap screening services. Research on HPV screening in developing countries raises concerns of commercial exploitation. Because Pap screening is feasible wherever cervical screening is appropriate, it is inappropriate to delay the development of Pap screening services pending research into HPV vaccines or alternative screening technologies. Quality management is the point at which public health and diagnostic pathology intersect and will remain an indispensable element of cervical screening programs irrespective of the screening test(s) eventually used. Pap screening in developing countries is an ethical imperative without a substantial political constituency and will benefit from the engagement of organized cytology.

KW - Cervical cancer

KW - Developing countries

KW - Ethics

KW - Vietnam

KW - War

UR - http://www.scopus.com/inward/record.url?scp=27744593120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744593120&partnerID=8YFLogxK

U2 - 10.1002/dc.20284

DO - 10.1002/dc.20284

M3 - Article

C2 - 16240403

AN - SCOPUS:27744593120

VL - 33

SP - 344

EP - 351

JO - Diagnostic Cytopathology

JF - Diagnostic Cytopathology

SN - 8755-1039

IS - 5

ER -